Effects of Early Use of Nitazoxanide in Patients With COVID-19
Status:
Completed
Trial end date:
2020-09-05
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, placebo-controlled, parallel, blinded, interventional, treatment
clinical trial with two arms.
Population: 392 Patients with COVID-19 (Coronavirus Disease-19), confirmed by RT-PCR (Real
Time polymerase chain reaction), symptomatic in the early phase of the disease.
Experimental group: 196 patients, nitazoxanide 500mg 8 / 8 hours for 5 days. Control group:
196 patients, placebo 8/8 hours for 5 days.
Phase:
Phase 2
Details
Lead Sponsor:
Universidade Federal do Rio de Janeiro
Collaborators:
ATCGen Complexo Hospitalar Municipal de São Caetano do Sul Hospital de Transplante Doutor Euryclides de Jesus Zerbini Hospital e Maternidade Therezinha de Jesus Ministry of Science and Technology, Brazil National Research Council, Brazil Santa Casa de Misericórdia de Sorocaba Secretaria de Estado de Saúde do Distrito Federal Secretaria Municipal de Saúde de Bauru Secretaria Municipal de Saúde de Guarulhos